Court lifts Medtronic’s RX catheter injunction
This article was originally published in The Gray Sheet
Executive Summary
A May 2000 injunction that has barred Medtronic from manufacturing or marketing rapid-exchange catheters will end Oct. 29, the date on which Abbott's RX patent was originally supposed to expire, the U.S. District Court for the Northern District of California 1ruled Oct. 21. The court concluded that Abbott would not suffer any material damage, and that lifting the ban suits the public interest and the spirit of the Patent Term Restoration Act. The ruling follows a one-year interim patent extension granted to Abbott on Oct. 14 by the U.S. Patent and Trademark Office (2"The Gray Sheet" Oct. 20, 2008, In Brief). Medtronic says it will announce its commercial plans after Oct. 29. The firm may choose to launch despite the extension and risk modest infringement damages if a full extension is granted, according to Morgan Stanley analyst David Lewis
You may also be interested in...
Abbott gains RX catheter patent extension
U.S. Patent and Trademark Office grants Abbott a one-year interim extension Oct. 14 for its coveted rapid-exchange catheter patent, set to expire Oct. 29. Abbott had filed for a nearly three-year extension on July 25 for the patent, which was originally granted to Dr. Paul Yock in 1995 (1"The Gray Sheet" Sept. 1, 2008, p. 3). Competitors AngioScore and Medtronic oppose the extension. PTO believes the patent qualifies for full extension, but FDA has not yet completed its portion of the patent extension review. Abbott's attorneys met with PTO on Sept. 3 to discuss products that utilize the Yock patent; prior litigation involving the patent, including a Medtronic lawsuit and motion to lift an injunction barring Medtronic from using RX catheters; and an Aug. 19 citizen's petition filed by AngioScore opposing the extension. The physician-preferred RX catheter delivery system is particularly important to Medtronic's stent business, the firm says
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.